GLP1R and heart failure: While both types of drug decrease cardiorenal risk, SGLT2 inhibitors primarily reduce the risk of heart failure hospitalisation, whereas GLP-1 RAs mainly reduce the risk of stroke and myocardial infarction [14, 15].